X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1499) 1499
Conference Proceeding (894) 894
Book Review (151) 151
Publication (63) 63
Book / eBook (5) 5
Book Chapter (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gastroenterology & hepatology (1435) 1435
humans (704) 704
index medicus (699) 699
male (432) 432
female (416) 416
adult (400) 400
middle aged (287) 287
crohn's disease (269) 269
inflammatory-bowel-disease (221) 221
abridged index medicus (217) 217
crohns-disease (201) 201
inflammatory bowel disease (191) 191
ulcerative colitis (178) 178
gastroenterology and hepatology (164) 164
ulcerative-colitis (158) 158
adolescent (151) 151
infliximab (144) 144
aged (138) 138
crohn disease - drug therapy (129) 129
treatment outcome (114) 114
risk factors (99) 99
inflammatory bowel diseases (89) 89
crohns disease (86) 86
young adult (82) 82
therapy (80) 80
pharmacology & pharmacy (78) 78
care and treatment (74) 74
crohn disease - pathology (71) 71
severity of illness index (71) 71
crohn disease - genetics (66) 66
remission (64) 64
antibodies, monoclonal - therapeutic use (63) 63
child (61) 61
double-blind method (61) 61
remission induction (61) 61
adalimumab (60) 60
inflammatory bowel-disease (60) 60
crohn disease - diagnosis (58) 58
surgery (58) 58
clinical trials (56) 56
follow-up studies (56) 56
patients (55) 55
recurrence (55) 55
analysis (53) 53
time factors (53) 53
tumor necrosis factor-alpha - antagonists & inhibitors (53) 53
animals (51) 51
crohn disease - immunology (51) 51
immunosuppressive agents - therapeutic use (51) 51
crohn disease - complications (50) 50
endoscopy (50) 50
gastrointestinal diseases (50) 50
retrospective studies (50) 50
colitis, ulcerative - drug therapy (49) 49
risk (48) 48
azathioprine (47) 47
case-control studies (47) 47
colitis (47) 47
maintenance therapy (47) 47
prospective studies (47) 47
gastrointestinal agents - therapeutic use (46) 46
medicine, general & internal (45) 45
c-reactive protein (44) 44
epidemiology (44) 44
ibd (44) 44
incidence (44) 44
crohn disease - surgery (43) 43
gastroenterology (43) 43
immunology (43) 43
inflammation (43) 43
mice (43) 43
inflammatory bowel diseases - drug therapy (42) 42
intestine (42) 42
life sciences (42) 42
research (42) 42
aged, 80 and over (41) 41
anti-inflammatory agents - therapeutic use (40) 40
crohn disease - epidemiology (40) 40
diagnosis (40) 40
prevalence (40) 40
efficacy (39) 39
intestinal mucosa - pathology (39) 39
medical research (39) 39
prognosis (39) 39
quality of life (38) 38
rheumatoid-arthritis (38) 38
colitis, ulcerative - diagnosis (37) 37
chemical sciences (36) 36
health aspects (35) 35
management (35) 35
medical colleges (35) 35
monoclonal antibodies (35) 35
organic chemistry (35) 35
studies (35) 35
induction (34) 34
antibodies, monoclonal - adverse effects (33) 33
association (32) 32
colon (32) 32
crohn disease - microbiology (32) 32
medicine, experimental (32) 32
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2003, Baillière's best practice & research., Volume 17, no. 1., 137
Book
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 711 - 721
Journal Article
Gut, ISSN 0017-5749, 05/2017, Volume 66, Issue 5, pp. 839 - 851
ObjectiveVedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an... 
INFLAMMATORY-BOWEL-DISEASE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | OPPORTUNISTIC INFECTIONS | FOLLOW-UP | RISK | EXPERIENCE | COHORT | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | ADVERSE EVENTS | MAINTENANCE THERAPY | Tuberculosis - epidemiology | Age Factors | Humans | Middle Aged | Male | Narcotics - therapeutic use | Clostridium Infections - epidemiology | Adrenal Cortex Hormones - therapeutic use | Incidence | Young Adult | Treatment Failure | Infusions, Intravenous - adverse effects | Gastrointestinal Agents - immunology | Adult | Female | Colitis, Ulcerative - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Sepsis - epidemiology | Chemical and Drug Induced Liver Injury - epidemiology | Randomized Controlled Trials as Topic | Crohn Disease - drug therapy | Gastrointestinal Agents - therapeutic use | Gastrointestinal Agents - adverse effects | Antibodies, Monoclonal, Humanized - immunology | Antibodies, Neutralizing - blood | Leukoencephalopathy, Progressive Multifocal - epidemiology | Neoplasms - epidemiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug therapy | Crohn's disease | Ulcerative colitis | Clinical trials | Infections | Malignancy | Patients | Risk factors | Crohns disease | Inflammatory bowel disease | Studies | Tuberculosis | Tumor necrosis factor | Population | Tumor necrosis factor-TNF | TNF inhibitors | Sepsis | Safety | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus | 1506 | Inflammatory Bowel Disease
Journal Article
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, ISSN 1542-3565, 03/2019, Volume 17, Issue 4, pp. 796 - 797
Journal Article
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, ISSN 1542-3565, 02/2019, Volume 17, Issue 3, pp. 573 - 574
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 699 - 710
Journal Article
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, ISSN 1542-3565, 03/2016, Volume 14, Issue 3, pp. 483 - 483
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 1, pp. 96 - 109.e1
Journal Article
LANCET, ISSN 0140-6736, 12/2017, Volume 390, Issue 10114, pp. 2768 - 2768
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 1, pp. 85 - 95
Journal Article